(1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: A wingless β-catenin agonist that increases bone formation rate

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 6962-6965

  Pelletier, Jeffrey C ^a   Lundquist IV, Joseph T ^a   Gilbert, Adam M ^b   Alon, Nipa ^b   Bex, Frederick J ^a   Bhat, Bheem M ^a   Bursavich, Mattew G ^b   Coleburn, Valerie E ^a   Felix, Luciana A ^a   Green, Daniel M ^a   Green, Paula ^a   Hauze, Diane B ^a   Kharode, Yogendra P ^a   Lam, Ho Sun ^a   Lockhead, Susan R ^a   Magolda, Ronald L ^a   Matteo, Jeanne J ^a   Mehlmann, John F ^a   Milligan, Colleen ^a   Murrills, Richard J ^a   Pirrello, Jennifer ^a   Selim, Sally ^a   Sharp, Michael C ^a   Unwalla, Ray J ^a   Vera, Matthew D ^a   Wrobel, Jay E ^a   Yaworsky, Paul ^a   Bodine, Peter V N ^a   more..

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 (4 (NAPHTHALEN 2 YL)PYRIMIDIN 2 YL)PIPERIDIN 4 YL)METHANAMINE; BETA CATENIN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; WAY 262611; WNT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MOLECULAR SIZE; NONHUMAN; OSSIFICATION; OVARIECTOMY; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRABECULAR BONE;

ANIMALS; BETA CATENIN; CATALYTIC DOMAIN; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MODELS, MOLECULAR; OSTEOGENESIS; PIPERIDINES; PYRIMIDINES; RATS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 70949108320     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9014197     Document Type: Article

References (22)

1. (a) Logan, C. Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 781-810.
2. (b) Moon, R. T.; Kohn, A. D.; De Ferrari, G. V.; Kaykas, A. Wnt and β-catenin signaling: diseases and therapies. Nat. Rev. Genet. 2004, 5, 689-699.
3. (a) Shahnazari, M.; Yao, W.; Corr, M.; Lane, N. E. Targeting the Wnt signaling pathway to augment bone formation. Curr. Osteoporosis Rep. 2008, 6, 142-148.
4. (b) Kubota, T.; Michigami, T.; Ozono, K. Wnt signaling in bone metabolism. J. Bone Miner. Metab. 2009, 27, 265-271.
5. (c) Mao, B.; Wu, W.; Dividson, G.; Marhold, J.; Li, M.; Mechler, B. M.; Delius, H.; Hoppe, D.; Stannek, P.; Walter, C.; Glinka, A.; Niehrs, C. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signaling. Nature 2002, 417, 664-667. (Pubitemid 34614827)
6. (a) Boyden, L. M.; Mao, J.; Belsky, J.; Mitzner, L.; Farhi, A.; Mitnick, M. A.; Wu, D.; Insogna, K.; Lifton, R. P. High bone density due to a mutation in LDL receptor related protein 5. N. Engl. J. Med. 2002, 346, 1513-1521.
7. (b) Little, R. D.; Carulli, J. P.; Del Mastro, R. G.; Dupuis, J.; Osborne, M.; Folz, C.; Manning, S. P.; Swain, P. M.; Zhoa, S.-C.; Eustace, B.; Lappe, M. M.; Spitzer, L.; Zweier, S.; Braunschweiger, K. A mutation in the LDL receptor related protein 5 results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 2002, 70, 11-19.
8. (c) Johnson, M. L. The high bone mass family: the role of Wnt/Lrp5 signalling in the regulation of bone mass. J. Musculoskeletal Neuronal Interact. 2004, 4, 135-138.
9. (a) Chan, A.; van Bezooijen, R. L.; Lowik, C. W. G. M. A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Curr. Opin. Invest. Drugs 2007, 8, 293-298.
10. (b) Niida, A.; Hiroko, T.; Kasai,M.; Furukawa, Y.; Nakamura, Y.; Suzuki, Y.; Sugano, S.; Akiyama, T. Dkk-1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene 2004, 1-7.
11. (c) Baron, R.; Rawadi, G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148, 2635-2643. (Pubitemid 46984775)
12. Bhat, B. M.; Allen, K. M.; Liu, W.; Graham, J.; Morales, A.; Anisowicz, A.; Lam, H.-S.; McCauley, C.; Coleburn, V.; Cain, M.; Fortier, E.; Bhat, R. A.; Bex, F. J.; Yaworsky, P. J. Structure-based mutation analysis shows the importance of LRP5 β-propeller 1 in modulating Dkk 1-mediated inhibition of Wnt signaling. Gene 2007, 391, 103-112.
13. Ring, D. B.; Johnson, K. W.; Henriksen, E. J.; Nuss, J. M.; Goff, D.; Kinnick, T. R.; Ma, S. T.; Reeder, J. W.; Samuels, I; Slabiak, T.; Wagman, A. S.; Wernette-Hammond, M.-E.; Harrison, S. D. Selective glycogen synthase kinase inhibitors potentiate insulin activation of glucose transport utilization in vitro and in vivo. Diabetes 2003, 52, 588-595.
14. Lui, J.; Wu, X.; Mitchell, B.; Kintner, C.; Ding, S.; Schultz, P. G.A small-molecule agonist of the wnt signaling pathway. Angew. Chem., Int. Ed. 2005, 44, 1987-1990. (Pubitemid 40483016)
15. The GSK-3β kinase assay was performed essentially as described by the manufacturer (Upstate Biotechnology/Millipore Corporation, Billerica, MA).
16. McMartin, C.; Bohacek, R. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344. Docking details are provided in Supporting Information .
17. Bertrand, J.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H.; Flocco, M. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol. 2003, 333, 393-1347
18. Bursavich, M. G.; Lombardi, S.; Gilbert, A.M. Expedient parallel synthesis of 2-amino-4-heteroarylpyrimidines. Org. Lett. 2005, 7, 4113-4116.
19. Ioachim, E.; Medlycott, E. A.; Polson, M. I. J.; Hanan, G. S. Synthesis of a novel series of 6,6′-disubstituted-4,4′-bipyrimidines by radical anion coupling: new π-accepting ligands for coordination chemistry. Eur. J. Org. Chem. 2005, 3775-3780.
20. Di, L.; Kerns, E. H. Application of pharmaceutical profiling assays for optimization of drug-like properties. Curr. Opin. Drug Discovery Dev. 2005, 8, 495-504.
21. Kharode, Y. P.; Sharp, M.C.; Bodine, P.V.N. Utility of the Ovariectomized Rat as a Model for Human Osteoporosis in Drug Discovery. In Osteoporosis: Methods and Protocols; Westendorf, J. J., Ed.; Methods in Molecular Biology, Vol.455; Humana Press: Totowa, NJ, 2008; Chapter 8, pp 111-124.
22. Robinson, J. A.; Chatterjee-Kishore, M.; Yaworsky, P. J.; Cullen, D. M.; Zhao, W.; Li, C.; Kharode, Y.; Sauter, L.; Babij, P.; Brown, E. L.; Hill, A. A.; Akhter, M. P.; Johnson, M. L.; Recker, R. R.; Komm, B. S.; Bex, F. J. Wnt/β-catenin is a normal physiological response to mechanical loading in bone. J. Biol. Chem. 2006, 281, 31720-31728.